- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06316076
Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases
A Clinical Study for the Safety and Efficacy of CD19-CAR-DNT Cells (RJMty19) in the Treatment of Relapsed or Refractory Autoimmune Diseases
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Qiong Fu, MD, PHD
- Phone Number: +086-13585603288
- Email: fuqiong@renji.com
Study Locations
-
-
-
Shanghai, China
- Recruiting
- Department of Rheumatology, Ren Ji Hospital South Campus, School of Medicine, Shanghai JiaoTong University
-
Contact:
- Qiong Fu, MD, PhD
- Phone Number: 86-13585603288
- Email: fuqiong@renji.com
-
Contact:
- Shuang Ye, MD, PhD
- Phone Number: 86-15801706421
- Email: Yeshuang@renji.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Voluntarily sign an ICF and expect to complete the study procedures for follow-up examinations and treatment;
- Aged 18 to 75 years (including cut-offs), regardless of gender;
Appropriate organ function, and accordance with the following criteria within 7 days prior to lymphodepleting chemotherapy:
Coagulation function: a) Fibrinogen ≥1.0 g/L; b) Activated partial thromboplastin time ≤1.5 times the upper limit of normal (ULN); c) Prothrombin time (PT) ≤1.5 times ULN;
Liver function: a) Glutathione aminotransferase (AST) ≤ 3 times the upper limit of normal (ULN); b) Glutamic aminotransferase (ALT) ≤ 3 times ULN; c) Total bilirubin ≤ 1.5 times ULN, unless the subject has documented Gilbert syndrome. Subjects with Gilbert-Meulengracht syndrome with total bilirubin ≤ 1.5 times ULN may be included;
Renal function: serum creatinine ≤ 1.5 times ULN, or creatinine clearance ≥ 60 mL/min (see Appendix 2 for Cockcroft-Gault formula);
Complete blood count: a) Hemoglobin ≥ 80 g/L or hemoglobin maintained at that level following transfusion; b) absolute neutrophil count (ANC) ≥ 1.0×10^9/L; c) A platelet count ≥ 30 x 10^9/L or a platelet count maintained at that level following a platelet transfusion;
Cardiopulmonary function: left ventricular ejection fraction (LVEF) ≥45%;
Female patients with of childbearing potential should have a negative pregnancy test during the screening period. Any male and female patients of childbearing potential must agree to use an effective contraception method for at least six months from the time that they sign the informed consent form until the end of the cell infusion. Female patients without childbearing potential (meeting at least 1 of the following criteria) is described below:
- Have undergone a hysterectomy or bilateral oophorectomy;
- Medically recognized as ovarian failure;
- Medically recognized as post-menopausal (at least 12 consecutive months of menopause without pathological or physiological cause);
- Meets the criteria of relapsed/refractory autoimmune diseases in 2022 EULAR/ACR.
Exclusion Criteria:
- Individuals with a history of severe drug allergies or allergic constitution;
- Active infectious diseases: such as tuberculosis, central nervous system infection, hepatitis, enteritis, etc.;
- The following serious diseases: malignant tumor, end-stage renal failure, alveolar hemorrhage requiring mechanical ventilation, acute mononeuritis multiplex, or CNS involvement;
- Renal disease: creatinine clearance rate < 60mL/min and serum creatinine > 1.5 times ULN within 1 week before lymphodepleting chemotherapy; Patients required hemodialysis or high-dose glucocorticoid therapy (e.g., prednisone (or equivalent) ≥100mg per day) within 6 months before screening;
- Cardiovascular disease: unstable angina, cerebrovascular accident or transient ischemic attack, myocardial infarction, New York Heart Association class III or IV cardiac dysfunction, or refractory hypertension within 6 months before screening (refractory hypertension was defined as: on the basis of lifestyle modification, patients were treated with adequate and reasonably tolerable doses of ≥3 antihypertensive drugs (including diuretics) for > 1 month or with ≥4 antihypertensive drugs for effective blood pressure control) and a history of severe arrhythmia requiring drug treatment;
- Other uncontrollable diseases: clinically unstable or not effectively controlled acute/chronic diseases unrelated to AID (such as acute pneumonia, diabetic ketoacidosis, acute pancreatitis, etc.) that may confound study results or affect investigators' assessment of efficacy/safety;
- Patients with positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and peripheral blood hepatitis B virus (HBV) DNA titration assay not within the normal reference range, positive hepatitis C virus (HCV) antibody and peripheral blood HCV RNA, positive for human immunodeficiency virus (HIV), or positive for cytomegalovirus (CMV) DNA, or positive syphilis test;
- The presence of active or uncontrollable infections requiring systemic treatment (except simple urinary tract infections or upper respiratory tract infections) and currently receiving suppressive therapy for any chronic infection (e.g., tuberculosis, Pneumocystis carinii, cytomegalovirus, herpes simplex virus, herpes zoster, and atypical mycobacteria);
- Vaccination with live or attenuated live vaccine within 1 month before screening;
- Persons who have previously received an organ transplant or are preparing to receive an organ transplant;
- Patients have received CAR-T therapy or other gene-modified cell therapy prior to enrolment;
- Received rituximab treatment within 6 months prior to screening; Received belimumab and telitacicept within 30 days prior to initial administration of the investigational drug; JAK inhibitor discontinuation time is less than 5 half-lives;
- Patients with a life expectancy of less than 3 months;
- Patients have been involved in other clinical studies within 3 months prior to screening;
Patients, in the judgement of the investigator and/or clinical criteria, are contraindicated to any study procedure or have other medical conditions that may place them at unacceptable risk.
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CD19-CAR-DNT cells
8-24 patients are planned to be enrolled in the dose-escalation trial and 12-24 patients in the dose-expansion trial.
|
Lentiviral vector-transduced DNT cells to express anti-CD19 CAR.
Prior to cellular infusion, each patient received cyclophosphamide and fludarabine lymphodepleting chemotherapy.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of abnormalities
Time Frame: Up to 28 days
|
Incidence of abnormalities in AE/SAE/AESI/laboratory tests/electrocardiograms/vital signs.
|
Up to 28 days
|
DLT
Time Frame: Up to 28 days
|
To evaluate the safety, tolerability, and determine the recommended dosage of CD19-CAR-DNT Cell Therapy for Relapsed/Refractory autoimmune disease.
|
Up to 28 days
|
MTD
Time Frame: Up to 28 days
|
MTD was the highest dose for DLT in ≤1/6 subjects.
|
Up to 28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics (PK) indicator (Cmax)
Time Frame: Up to 90 days
|
The peak concentration of CD19-CAR-DNT cells amplified in the peripheral blood (Cmax, detected by qPCR).
|
Up to 90 days
|
Pharmacokinetics (PK) indicator (T1/2)
Time Frame: Up to 90 days
|
CD19-CAR-DNT cells blood concentrations will be measured at different time points to evaluate the elimination half-life in hours (T1/2).
T1/2 is defined as the time point when the concentration of CD19-CAR-DNT reaches half of maximum in a patient's peripheral blood (T1/2, detected by qPCR).
|
Up to 90 days
|
Pharmacokinetics (PK) indicator (AUC)
Time Frame: Up to 90 days
|
CD19-CAR-DNT cells blood concentrations will be measured at different time points to evaluate the area under the curve (AUC).
(AUC, detected by qPCR)
|
Up to 90 days
|
Pharmacokinetics (PK) indicator (Tmax)
Time Frame: Up to 2 years
|
CD19-CAR-DNT cells blood concentrations will be measured at different time points to evaluate the peak plasma time (Tmax).
Tmax is defined as the time to reach the highest concentration (Tmax, detected by qPCR).
|
Up to 2 years
|
Disease response rate at 6 months
Time Frame: Up to 6 months
|
Proportion of subjects with complete or partial remission.
|
Up to 6 months
|
Duration of Response
Time Frame: Up to 2 years
|
The time from the first assessment of remission or partial remission of the disease to the first assessment of disease progression or death from any cause.
|
Up to 2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Nervous System Diseases
- Skin Diseases
- Immune System Diseases
- Musculoskeletal Diseases
- Connective Tissue Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Skin Diseases, Vascular
- Systemic Vasculitis
- Lupus Erythematosus, Systemic
- Scleroderma, Systemic
- Myositis
- Autoimmune Diseases
- Vasculitis
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Cyclophosphamide
- Fludarabine
Other Study ID Numbers
- RJMty19-AID001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Lupus Erythematosus
-
SanofiCompletedCutaneous Lupus Erythematosus-Systemic Lupus ErythematosusJapan
-
Kyowa Kirin Co., Ltd.RecruitingHealthy Volunteers | Systemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)Japan
-
Second Xiangya Hospital of Central South UniversityNational Natural Science Foundation of China; Hunan Provincial Natural Science... and other collaboratorsActive, not recruitingCutaneous Lupus Erythematosus | Systemic Lupus Erythematosus RashChina
-
Novartis PharmaceuticalsNot yet recruitingSystemic Lupus Erythematosus, SLE
-
Changhai HospitalRui Therapeutics Co., LtdRecruitingSystemic Lupus Erythematosus (SLE)China
-
Bioray LaboratoriesFirst Affiliated Hospital of Zhejiang UniversityRecruitingSystemic Lupus Erythematosus (SLE)China
-
Sohag UniversityNot yet recruitingSystemic Lupus Erythematosus (SLE)
-
BiogenEnrolling by invitationSystemic Lupus Erythematosus (SLE)Spain, Bulgaria, United States, China, Serbia, Mexico, Korea, Republic of, Chile, Argentina, Poland, Japan, Romania, Colombia, Hungary, Czechia, United Kingdom, Taiwan, Brazil, Israel, France
-
AbbVieCompletedSystemic Lupus Erythematosus (SLE)United States, Argentina, Australia, Bulgaria, China, Colombia, Germany, Hungary, Italy, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Puerto Rico, Spain, Taiwan, United Kingdom
-
AmgenTerminatedActive Systemic Lupus ErythematosusKorea, Republic of, United States, Taiwan, Canada, Spain, Italy, Mexico, Japan, Turkey, Austria, Greece, Colombia, Switzerland, Poland, France, Bulgaria, Hong Kong, Russian Federation, Chile
Clinical Trials on CD19-CAR-DNT cells
-
Second Affiliated Hospital, School of Medicine,...Zhejiang Ruijiamei Biotechnologies, Co., Ltd.RecruitingB-cell Non-Hodgkin's LymphomaChina
-
Guangdong Ruishun Biotech Co., LtdRuijin Hospital; Southern Medical University, China; Beijing GoBroad HospitalNot yet recruitingB-cell Non-Hodgkin's Lymphoma
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingNon-hodgkin Lymphoma,B CellChina
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingAcute Lymphoblastic Leukemia | Non-hodgkin Lymphoma,B CellChina
-
Miltenyi Biomedicine GmbHRecruitingB-cell Lymphoma Refractory | B-cell Lymphoma Recurrent | Acute Lymphoblastic Leukemia Recurrent | Chronic Lymphocytic Leukemia Recurrent | Chronic Lymphocytic Leukemia RefractoryGermany
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingVasculitis | Amyloidosis | Autoimmune Hemolytic Anemia | POEMS SyndromeChina
-
Southwest Hospital, ChinaUnknownLymphoma, Large B-Cell, DiffuseChina
-
Zhejiang UniversityShanghai YaKe Biotechnology Ltd.Recruiting
-
University College, LondonEnrolling by invitationMultiple MyelomaUnited Kingdom
-
Miltenyi Biomedicine GmbHNot yet recruiting